Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Natan Ponieman

Clearmind: Positive Preclinical Evidence For Flagship Psychedelic Molecule, Looks To Human Trials Before Year End

Psychedelics biotech company Clearmind Medicine Inc. (OTC:CMNDF) has published information pertaining to the safety and efficacy of its flagship molecule, called MEAI or CMND-100, after its pre-IND meeting with the Food and Drug Administration on Wednesday.

MEAI is a proprietary psychedelic compound developed by Clearmind. The company is pushing to test the molecule in humans in order to assess its efficacy in the treatment of alcohol abuse disorder. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.